Biomea Fusion, Inc.

Biomea Fusion, Inc.

BMEA·NASDAQ

$1.38

+6.2%
HealthcareBiotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$82.10M
EPS-1.1800
P/E Ratio-1.17
Earnings Date08/03/2026

bmea

Short Term Debt

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Biomea Fusion, Inc.

Biomea Fusion, Inc. Competitors Analysis of Short Term Debt

BMEA · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
5.10M
23.2%-20.2%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
470.00K
N/AN/AN/A
403.00K
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
0.00
N/AN/AN/A
1.47M
N/AN/A15.8%
0.00
N/AN/AN/A
SRZN logo
Surrozen, Inc.
NASDAQ:SRZN
1.29M
N/AN/AN/A
3.87M
13.9%21.7%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Biomea Fusion, Inc.

Biomea Fusion, Inc. Fair Value Envelope

BMEA · NASDAQ

Our analysis suggests that BMEA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.38, this represents a potential HIDDEN relative to our calculated worth for Biomea Fusion, Inc..

Intrinsic Value
Current Price: $1.38